NCT07339553 2026-01-21Clinical Study of EZH2 Inhibitor Combined With PARP Inhibitor in the Treatment of Patients With Advanced or Recurrent Epithelial Ovarian Cancer.Peking University Third HospitalPhase 2 Not yet recruiting30 enrolled